Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | ACP3 | P15309 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 4/20 | 0.46 |
| ▸ | TDO2 | P48775 | 4/20 | 0.46 |
| ▸ | IDO2 | Q6ZQW0 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7917310 | 0.96 | ALDH1A1 (0.55) | TDP1ALDH1A1KMT2AGAAACP3 | |
| 2-Chlorophenyl-Bisphenylmethane(Major) SCHEMBL41575 | 0.88 | IDO1 (0.55) | TDP1ALDH1A1KMT2AGAAACP3 | |
| 2-Chlorophenyl-Bisphenylmethane(Major) SCHEMBL29279416 | 0.86 | IDO1 (0.57) | TDP1ALDH1A1KMT2AACP3IDO1 | |
| SCHEMBL1758062 | 0.81 | TDP1 (0.64) | TDP1ALDH1A1KMT2AGAAIDO1 | |
| SCHEMBL12221116 | 0.81 | IDO1 (0.46) | TDP1ALDH1A1KMT2AGAAACP3 | |
| SCHEMBL22694327 | 0.79 | IDO1 (0.56) | TDP1ALDH1A1KMT2AGAAIDO1 | |
| SCHEMBL36791 | 0.79 | IDO1 (0.56) | TDP1ALDH1A1KMT2AGAAIDO1 | |
| SCHEMBL19314626 | 0.79 | IDO1 (0.56) | TDP1ALDH1A1KMT2AGAAIDO1 | |
| SCHEMBL982047 | 0.79 | IDO1 (0.56) | TDP1ALDH1A1KMT2AGAAIDO1 | |
| SCHEMBL28546831 | 0.78 | TSHR (0.47) | TDP1ALDH1A1KMT2AGAAACP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0918514-B9 | TRIARYL METHANE COMPOUNDS FOR THE TREATMENT OF CANCER, ACTINIC KERATOSIS AND KAPOSI'S SARCOMA | HARVARD COLLEGE (US) | 2006-07-05 | — | — | EP | claimed |
| CN-1249018-C | Triaryl methane compounds for sickle cell disease | HARVARD COLLEGE (US) | 2006-04-05 | — | — | CN | claimed |
| EP-0918514-B1 | TRIARYL METHANE COMPOUNDS FOR THE TREATMENT OF CANCER, ACTINIC KERATOSIS AND KAPOSI'S SARCOMA | HARVARD COLLEGE (US) | 2005-12-28 | — | — | EP | claimed |
| US-20020119989-A1 | Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction | ANIONA APS (DK) | 2002-08-29 | — | — | US | claimed |
| EP-0918514-A4 | TRIARYL METHANE COMPOUNDS FOR SICKLE CELL DISEASE | HARVARD COLLEGE (US) | 2001-05-09 | — | — | EP | claimed |
| EP-1052990-A2 | CHEMICAL COMPOUNDS HAVING ION CHANNEL BLOCKING ACTIVITY FOR THE TREATMENT OF IMMUNE DYSFUNCTION | NEUROSEARCH A/S (DK) | 2000-11-22 | — | — | EP | claimed |
| CN-1251037-A | Triarylmethane compounds for sickle cell disease | HARVARD COLLEGE (US) | 2000-04-19 | — | — | CN | claimed |
| EP-0918514-A1 | TRIARYL METHANE COMPOUNDS FOR SICKLE CELL DISEASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1999-06-02 | — | — | EP | claimed |
| WO-1999025347-A2 | CHEMICAL COMPOUNDS HAVING ION CHANNEL BLOCKING ACTIVITY FOR THE TREATMENT OF IMMUNE DYSFUNCTION | NEUROSEARCH A/S (DK) | 1999-05-27 | — | — | WO | claimed |
| WO-1997034589-A1 | TRIARYL METHANE COMPOUNDS FOR SICKLE CELL DISEASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1997-09-25 | — | — | WO | claimed |
| US-7531573-B2 | potent, selective and safe inhibitors of the Ca2+-activated potassium channel | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531573-B2 | potent, selective and safe inhibitors of the Ca2+-activated potassium channel | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531573-B2 | potent, selective and safe inhibitors of the Ca2+-activated potassium channel | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-05-12 | — | — | US | disclosed |
| EP-0918514-B9 | TRIARYL METHANE COMPOUNDS FOR THE TREATMENT OF CANCER, ACTINIC KERATOSIS AND KAPOSI'S SARCOMA | HARVARD COLLEGE (US) | 2006-07-05 | — | — | EP | disclosed |
| CN-1249018-C | Triaryl methane compounds for sickle cell disease | HARVARD COLLEGE (US) | 2006-04-05 | — | — | CN | disclosed |
| WO-1999025347-A2 | CHEMICAL COMPOUNDS HAVING ION CHANNEL BLOCKING ACTIVITY FOR THE TREATMENT OF IMMUNE DYSFUNCTION | NEUROSEARCH A/S (DK) | 1999-05-27 | — | — | WO | disclosed |
| WO-1997034589-A1 | TRIARYL METHANE COMPOUNDS FOR SICKLE CELL DISEASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1997-09-25 | — | — | WO | disclosed |
| EP-0781128-A2 | CLOTRIMAZOLE METABOLITES IN THE TREATMENT OF SICKLE CELL DISEASE | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1997-07-02 | — | — | EP | disclosed |
| WO-1996008242-A9 | CLOTRIMAZOLE METABOLITES IN THE TREATMENT OF SICKLE CELL DISEASE | — | 1996-06-27 | — | — | WO | disclosed |
| WO-1996008242-A2 | CLOTRIMAZOLE METABOLITES IN THE TREATMENT OF SICKLE CELL DISEASE | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1996-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119989-A1 | Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction | KCNN2, KCNN1, KCNJ2 | TDP1 4201/4885ALDH1A1 2295/4885KMT2A 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.